Javascript must be enabled to continue!
Association Between Early Ventricular Arrhythmias and Mortality in Destination Vs. Bridge Patients on Continuous Flow LVAD Support
View through CrossRef
Abstract
Background: The association between ventricular arrhythmias (VAs) and mortality in patients supported by continuous flow left ventricular assist devices (LVAD) remains controversial. Objective: To evaluate the association between pre-implantation, early (≤30 day) post-implantation VAs and mortality in bridge to transplant (BTT) and destination therapy (DT) LVAD patients, separately. The risk factors for post LVAD VAs were also investigated.Methods: In this observational cohort study, we included 341 patients who received a first time, continuous flow LVAD between January 1st 2010 and July 30th 2018. We used Kaplan Meier curves and multivariable cox regression analyses to study the association between VAs and mortality in the BTT and DT populations.Results: The mean age of the cohort was 58 ± 14 years, with 82% males, 53% had ischemic cardiomyopathy, and 45% were DT. The mean follow-up was 2.2 ± 2.1 years. In both BTT and DT cohorts, pre LVAD VAs were not associated with mortality after LVAD implantation (log-rank p=0.95 and p=0.089, respectively). In the BTT population, early post-LVAD VAs were not statistically associated with increased mortality (log rank p=0.072). In the DT patients, early post LVAD VAs were associated with a 67 % increase in the hazards rate of mortality on LVAD support (HR 1.67 [1.05-2.65], p=0.029). The final model was adjusted for type of cardiomyopathy, INTERMACS profile, glomerular filtration rate, post LVAD atrial fibrillation, age and cerebrovascular events.Conclusion: Early post-LVAD VA is common after LVAD implantation and is an independent predictor of mortality in the DT LVAD population.
Research Square Platform LLC
Title: Association Between Early Ventricular Arrhythmias and Mortality in Destination Vs. Bridge Patients on Continuous Flow LVAD Support
Description:
Abstract
Background: The association between ventricular arrhythmias (VAs) and mortality in patients supported by continuous flow left ventricular assist devices (LVAD) remains controversial.
Objective: To evaluate the association between pre-implantation, early (≤30 day) post-implantation VAs and mortality in bridge to transplant (BTT) and destination therapy (DT) LVAD patients, separately.
The risk factors for post LVAD VAs were also investigated.
Methods: In this observational cohort study, we included 341 patients who received a first time, continuous flow LVAD between January 1st 2010 and July 30th 2018.
We used Kaplan Meier curves and multivariable cox regression analyses to study the association between VAs and mortality in the BTT and DT populations.
Results: The mean age of the cohort was 58 ± 14 years, with 82% males, 53% had ischemic cardiomyopathy, and 45% were DT.
The mean follow-up was 2.
2 ± 2.
1 years.
In both BTT and DT cohorts, pre LVAD VAs were not associated with mortality after LVAD implantation (log-rank p=0.
95 and p=0.
089, respectively).
In the BTT population, early post-LVAD VAs were not statistically associated with increased mortality (log rank p=0.
072).
In the DT patients, early post LVAD VAs were associated with a 67 % increase in the hazards rate of mortality on LVAD support (HR 1.
67 [1.
05-2.
65], p=0.
029).
The final model was adjusted for type of cardiomyopathy, INTERMACS profile, glomerular filtration rate, post LVAD atrial fibrillation, age and cerebrovascular events.
Conclusion: Early post-LVAD VA is common after LVAD implantation and is an independent predictor of mortality in the DT LVAD population.
Related Results
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
Abstract 15045: Impact of Left Ventricular Assist Device (LVAD) Type on Arrhythmic Outcomes in Patients With Continuous Flow LVADs
Abstract 15045: Impact of Left Ventricular Assist Device (LVAD) Type on Arrhythmic Outcomes in Patients With Continuous Flow LVADs
Introduction:
Cardiac arrhythmias are common in continuous flow left ventricular assist device (LVAD) recipients. The impact of axial vs. intrapericardial centrifugal L...
Patient‐Reported Outcomes Among Patients Pre– and Post–Left Ventricular Assist Device Implantation: A Retrospective and Comparative Study
Patient‐Reported Outcomes Among Patients Pre– and Post–Left Ventricular Assist Device Implantation: A Retrospective and Comparative Study
Introduction:
Despite many studies reporting the patient‐reported outcomes (PROs) of left ventricular assist device (LVAD) patients, there seem to be limited st...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Abstract 14995: Outcomes of Transcatheter Aortic Valve Replacements in Patients With Left Ventricular Assist Device
Abstract 14995: Outcomes of Transcatheter Aortic Valve Replacements in Patients With Left Ventricular Assist Device
Background:
The development or progression of aortic insufficiency (AI) to moderate to severe in patients with left ventricular assist devices (LVADs) for end stage hea...
Impact of deactivated CRT on ventricular arrhythmia occurrence and survival in LVAD patients
Impact of deactivated CRT on ventricular arrhythmia occurrence and survival in LVAD patients
Abstract
Background
The majority of LVAD patients with an active CRT device are CRT non-responders. Currently, there is n...

